MarketPulse
D

$DXCM

5 articles found
3 positive
0 negative
2 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Sotera Health Shares Surge 18% as Major Investor Trims $37M Stake

MIG Capital trims $37.4M Sotera Health stake while maintaining significant position. Company posts record profits, 20-year revenue growth streak amid 18% annual share price gain.
METAMSFTDXCMSHCCELHportfolio rebalancingrevenue growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Surgical Robots and Glucose Monitors Positioned for Decade-Long Growth Despite Competition

Intuitive Surgical and DexCom positioned for long-term growth despite near-term competition, driven by aging populations and untapped market opportunities.
MDTDXCMISRGlong-term investinggrowth stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

DexCom Positioned as Hidden Beneficiary in GLP-1 Drug Expansion

DexCom benefits from GLP-1 drug expansion as CGM devices are increasingly prescribed together, unlocking significant untapped patient markets and complementary revenue opportunities.
DXCMhealthcare stocksmedical devices
BenzingaBenzinga··Piero Cingari

Market Rally Broadens as Inflation Data Bolsters Rate-Cut Outlook

U.S. markets rally on softer inflation data boosting rate-cut expectations. Small-cap stocks, commodities, and growth sectors lead as investors bet on lower borrowing costs ahead.
DIADKNGCOINABNBQQQM+12earningsinflation